Human Securin(PTTG1) ELISA kit

Regulatory protein, which plays a central role in chromosome stability, in the p53/TP53 pathway, and DNA repair. Probably acts by blocking the action of key proteins. During the mitosis, it blocks Separase/ESPL1 function, preventing the proteolysis of the cohesin complex and the subsequent segregation of the chromosomes. At the onset of anaphase, it is ubiquitinated, conducting to its destruction and to the liberation of ESPL1. Its function is however not limited to a blocking activity, since it is required to activate ESPL1. Negatively regulates the transcriptional activity and related apoptosis activity of TP53. The negative regulation of TP53 may explain the strong transforming capability of the protein when it is overexpressed. May also play a role in DNA repair via its interaction with Ku, possibly by connecting DNA damage-response pathways with sister chromatid separation.

1. the short form of securin does not influence the expression of MYC transcriptional targets, such as TP53 and IL-8. PMID: 29989583
2. Data strongly indicated that PTTG1 is a target gene of miR186 in osteosarcoma (OS) cells and is involved in miR186mediated suppressive effects of OS cells. PMID: 29693191
3. Results show that PTTG1 oncoprotein overexpression may modulate cell proliferation-related regulators in myeloid leukemia. PMID: 29649138
4. In ACTH-secreting pituitary tumors, IHC staining showed strong cytoplasmic and moderate nucleic PTTG immunoreactivity in 22 of 28 nonrecurrent tumors and in 21 of 27 recurrent tumors but no staining in the 2 normal pituitaries. PTTG was significantly increased in both the nonrecurrent and recurrent groups compared with normal pituitary glands, but there was no difference between the nonrecurrent and recurrent groups. PMID: 29432944
5. Smurf1 interacts with and targets Securin, an inhibitor of sister-chromatid separation, for poly-ubiquitination and proteasomal degradation. PMID: 28658604
6. PTTG-1 oexpression in meningiomas were correlated with tumor grade and proliferation rate. PMID: 29575197
7. Results found that PTTG1 expression was significantly increased in androgen-independent prostate cancer cells and, elucidates that interleukin-6/STAT3 activation can increase PTTG1 expression and, consequently, promote the resistance to androgen deprivation therapy in castration-resistant prostate cancer by inducing EMT and increasing the cancer stem cell population. PMID: 29288516
8. we confirmed the oncogenic function of PTTG1 in BC and demonstrated that PTTG1 is a target of miR-146a-3p. PMID: 27893422
9. PTTG1 is an independent prognostic factor and acts as an oncogene in colorectal cancer PMID: 28219049
10. High PTTG1 expression is associated with aggressive meningiomas. PMID: 26894859
11. These results indicate PTTG1 may be a valuable biomarker in ovarian cancer to predict sensitivity to saracatinib, and could form the basis of a targeted prospective saracatinib trial for ovarian cancer. PMID: 27766744
12. A relatively stable genome in retinoblastoma tumor cells is maintained by TRb1 and TRb2-mediated PTTG1 inhibition, counteracting Rb-deficiency-related genomic instability. PMID: 28242412
13. Findings indicate that PBF and PTTG have a critical role in promoting thyroid cancer that is predictive of poorer patient outcome. PMID: 28504713
14. PTTG-mediated FGF2 upregulation is associated with more aggressive tumor features in patients with acromegaly. Also, locally produced estrogen through aromatization might have a role in this phenomenon. PMID: 26578364
15. All these suggest that the MAP3K M1P site is a potential interacting partner of MAP3K SH3 domain, which may mediate the intermolecular recognition between hPTTG1 and MAP3K. PMID: 27787230
16. that PTTG1 is a novel downstream target gene of androgen receptor and take part in prostate cancer proliferation and metastasis PMID: 27756608
17. Knockdown of PTTG1 suppresses the growth and invasion of LAC cells through upregulation of the TGFbeta1/SMAD3 signaling. PMID: 25816405
18. PTTG1 is correlated with non-small cell lung cancer (NSCLC) progression and as an independent poor prognostic factor in NSCLC patients. PMID: 27829547
19. Our data indicate that securin expression may serve as a strong and independent prognosticator of breast cancer outcome PMID: 26984614
20. PTTG1 mRNA expression levels in gastric tumor tissues were significantly higher than in the corresponding adjacent normal gastric mucosa.PTTG1 mRNA and protein expression are independent prognostic factors for gastric cancer patient survival. PMID: 25627474
21. Pttg1 may increase BC cell growth through nuclear exclusion of p27, which highlights a novel molecular regulatory machinery in tumorigenesis of BC. PMID: 26824458
22. Data show that overexpression of c-myc proto-oncogene protein could prevent the metabolic shift induced by pituitary tumor-transforming gene (PTTG) knockwown. PMID: 26516926
23. Report feedback loop between PTTG1 targeting miRNAs, PTTG1 and p53 that promotes pituitary tumorigenesis. PMID: 26320179
24. knockdown of PTTG1 increased expression of integrin alpha 4 (ITGA4), ITGA5, and integrin beta 1 (ITGB1); otherwise, RhoA expression was significantly decreased PMID: 26900962
25. Data show that pituitary tumor-transforming 1 protein (PTTG1) is over-expressed in multiple myeloma (MM) patients and is associated with poor survival. PMID: 26445238
26. Silencing of PTTG could also inhibit tumor growth, invasion, and angiogenesis in vivo. Our data indicated that PTTG might be a potential target for glioma treatment PMID: 25908389
27. FoxM1 binds to PTTG1 promoter to enhance PTTG1 transcription, and FoxM1-PTTG1 pathway promotes colorectal cancer migration and invasion PMID: 26264222
28. we demonstrated here the inhibitory effect of CACP on the growth of H22 cells in vitro and in vivo, which may be through, at least partly, repression of PTTG1 and then followed by the inactivation of P13/Akt and activation of p38 MARK signaling pathways PMID: 25874498
29. PTTG1 enhances HBV replication through suppression of P53. PMID: 26710612
30. In peripheral area of testicular seminoma, PTTG1 staining was located in cell nucleus. In central area, staining was more intense in cytoplasm. On the other hand, in embryonal carcinoma, cells had diffuse positive staining, mainly in cytoplasm. PMID: 24754453
31. PTTG1 is differentially expressed by benign and malignant pheochromocytoma with low sensitivity; meaning that positive immunohistochemistry result for PTTG1 is of great value to predict malignant behavior of pheochromocytoma PMID: 25871022
32. PTTG1 is a marker for proliferative skin diseases associated with cell cycle regulation and may aid in detection of aggressive cancers PMID: 25549700
33. Our findings provide novel molecular insights into hPTTG1-induced senescence and identify a novel mechanism by which hPTTG1 promotes metastasis by regulating the senescence-associated microenvironment. PMID: 22789011
34. The interaction between TERT and PTTG1 by association of Ku70 might be important for the enhancement of the limited self-renewal activity of MSCs and for understanding the regulatory mechanisms of self-renewal. PMID: 24816985
35. This study demonstrated that PTTG was expressed in most of meningioma tissues, and the degree of PTTG immunostaining was variable in the subtypes of tumors PMID: 24908230
36. This present meta-analysis suggests that PTTG expression may be associated with tumor invasiveness and microvessel density of pituitary adenomas. PMID: 24594688
37. The numbers of migrating cells (51.38 +/- 4.71) in the PTTG siRNA group was obviously lower. PMID: 24377512
38. Data indicate that pituitary tumor-transforming gene 1 (PTTG1) was frequently overexpressed in oral squamous cell carcinoma (OSCC) tissues. PMID: 24879625
39. PTTG may contribute to the malignant progression of esophageal squamous cell carcinoma (ESCC) and serve as a novel prognostic indicator for patients with ESCC. PMID: 24176776
40. our data suggest that PTTG1 promotes the proliferation of prostate cancer cells via the inhibition of SMAD3. SMAD3 thus appears to be a novel therapeutic target for suppressing the growth of prostate cancer. PMID: 24627133
41. high Cdc20 and securin immunoexpression identified a patient subgroup with extremely short, on average 2.4 years, breast cancer survival and triple-negative breast cancer subtype. PMID: 24853182
42. findings suggest that PTTG1 may act as a major target of miR-655. This study improves our understanding of the mechanisms underlying ESCC pathogenesis PMID: 24314023
43. No TTF1 or EAP1 germline mutations were associated with central pubertal disorders. TTF1 and EAP1 may affect puberty by changing expression in response to other members of puberty-associated gene networks PMID: 24051510
44. STAT3 induces PTTG expression to facilitate tumor growth and metastasis. PMID: 23416975
45. KLF6 directly binds and represses PTTG1 expression during induction of myeloid differentiation. PMID: 23977008
46. The expression of hPTTG1 was correlated with differentiation levels, clinical classification and lymph node metastasis, but did not correlate with gender, age or pathological types. PMID: 23128677
47. Overexpression of PTTG1, which encodes securin, a negative regulator of p53, was identified as a marker of poor survival in adrenocortical carcinoma. PMID: 24238056
48. These results define hPTTG as having a central role in thyroid autocrine signaling mechanisms via growth factors, with profound implications for promotion of transformed cell growth. PMID: 23867215
49. Enhanced expression of PTTG1 in the psoriatic epidermis may result in aberrant regulation of the cell cycle and impaired differentiation via the interplay between PTTG1 and TNF-alpha. PMID: 23677169
50. This study identified both PTTG1 and miR-186 as potential anti-invasion targets for therapeutic intervention in non-small cell lung cancer . PMID: 23671127

显示更多

收起更多

Cytoplasm. Nucleus.

Securin family

Expressed at low level in most tissues, except in adult testis, where it is highly expressed. Overexpressed in many patients suffering from pituitary adenomas, primary epithelial neoplasias, and esophageal cancer.

HGNC: 9690

OMIM: 604147

KEGG: hsa:9232

STRING: 9606.ENSP00000344936

UniGene: Hs.350966